UniQure has sold off the rights to its experimental gene therapy for hemophilia B, announcing this week that it is licensing the treatment to CSL Behring for $450 million in cash. The Dutch gene therapy developer could receive as much as $1.6 billion more in conditional payments if the gene therapy, currently in late-stage testing, progresses as expected. Per deal terms, CSL will also reimburse UniQure’s remaining development costs, cover expenses related to regulatory submissions and give UniQure royalties on net sales. The deal gives the biotech enough cash to fund itself for another four years and develop its other experimental gene therapies. Learn More